Safety of formoterol by Turbuhaler® as reliever medication compared with terbutaline in moderate asthma

European Respiratory Journal

Volumn 20, Issue 4, 2002, Pages 859-866

  Ind, P W ^a   Villasante, C ^a   Shiner, R J ^a   Pietinalho, A ^a   Boszormenyi N G ^a   Soliman, S ^a   Selroos, O ^a  

^a NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

As needed; Asthma; Formoterol; Oxis ; Tolerability; Turbuhaler

Indexed keywords

CORTICOSTEROID; FORMOTEROL; POTASSIUM; PREDNISOLONE; STEROID; TERBUTALINE;

ADULT; ARTICLE; ASTHMA; BACKACHE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEVICE; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; LUNG FUNCTION TEST; LUNG INFECTION; MALE; MUSCLE CRAMP; PEAK EXPIRATORY FLOW; PHARYNGITIS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SYMPTOMATOLOGY; TREMOR; VIRUS INFECTION;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; ASTHMA; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PROBABILITY; RESPIRATORY FUNCTION TESTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TERBUTALINE; TREATMENT OUTCOME;

EID: 0036799282     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.02.00278302     Document Type: Article

References (29)

1. Sheffer AL, Bartal M, Bousquet J et al. Global Strategy for Asthma Management and Prevention NHLBI/WHO Workshop Report. Publication No. 95-3659. Bethesda, MD, National Institutes of Health, National Heart, Lung and Blood Institute, 1995.
2. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994; 344: 219-224.
3. Pauwels RA, Löfdahl C-G, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 1997; 337: 1405-1411.
4. van der Molen T, Postma DS, Turner MO, et al. Effects of the long acting β-agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. Thorax 1997; 52: 535-539.
5. O'Byrne PM, Barnes PJ, Rodriguez-Roisin R, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 2001; 164: 1392-1397.
6. Seberovà E, Andersson A. Oxis (formoterol given by Turbuhaler) showed as rapid an onset of action as salbutamol given by a pMDI. Respir Med 2000; 94: 607-611.
7. Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997; 10: 2484-2489.
8. Malolepszy J, Böszörmény NG, Brander R, Larsson P. Formoterol 90 μg via Turbuhaler was safe in patients with acute bronchoconstriction. Eur Respir J 1998; 12: Suppl. 28, 323s.
9. Politiek MJ, Boorsma M, Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur Respir J 1999; 13: 988-992.
10. Grönneröd TA, von Berg A, Schwabe G, Soliman S. Formoterol via Turbuhaler® gave better protection than terbutaline against repeated exercise challenge for up to 12 hours in children and adolescents. Respir Med 2000; 94: 661-667.
11. 2-agonist formoterol. Am Rev Respir Dis 1991; 143: 998-1001.
12. Tattersfield AE, Löfdahl C-G, Postma DS, et al. Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet 2001; 357: 257-261.
13. O'Connor BJ, McSorley LC, Turbitt ML. Use of formoterol (Oxis®) Turbuhaler® as needed in moderate to severe asthma reduces the number of inhalers used whilst maintaining effectiveness. J Allergy Clin Immunol 2001; 107: A360.
14. Arvidsson P, Larsson S, Löfdahl C-G, Melander B, Wåhlander L, Svenmyr N. Formoterol, a new long-acting bronchodilator for inhalation. Ear Respir J 1989; 2: 325-330.
15. Arvidsson P, Larsson S, Löfdahl C-G, Melander B, Svenmyr N, Wåhlander L. Inhaled formoterol during one year in asthma: a comparison with salbutamol. Eur Respir J 1991; 4: 1168-1173.
16. Midgren B, Melander B, Persson G. Formoterol, a new long-acting β2-agonist, inhaled twice-daily, in stable asthmatic subjects. Chest 1992; 101: 1019-1022.
17. 2-agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma. Thorax 1990; 45: 259-261.
18. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1987; 136: 225-244.
19. Quanjer PhH. Standardized lung function testing. Eur Respir J 1993; 6: Suppl. 16, 5-40.
20. Au DH, Lemaitre RN, Curtis JR, Smith NL, Psaty BM. The risk of myocardial infarction associated with inhaled β-adrenoceptor agonists. Am J Respir Crit Care Med 2000; 161: 827-830.
21. Au DH, Curtis JR, Psaty BM. Risk of myocardial ischaemia and β-adrenoceptor agonists. Ann Med 2001; 33: 287-290.
22. Tötterman KJ, Huhti L, Sutinen E, et al. Tolerability to high doses of formoterol and terbutaline via Turbuhaler® for 3 days in stable asthmatic patients. Ear Respir J 1998; 12: 573-579.
23. Schreurs AJM, Sinninghe Damsté HE, de Graaff CS, Greefhorst AP. A dose-response study with formoterol Turbuhaler as maintenance therapy in asthmatic patients. Eur Respir J 1996; 9: 1678-1683.
24. Palmer JB, Stuart AM, Shepherd GL, Viskum K. Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstructive airways disease - a 3-month comparison of the efficacy and safety of twice-daily salmeterol (100 μg) with salmeterol (50 μg). Respir Med 1992; 86: 409-417.
25. Ekström T, Ringdal N, Sobradillo V, Runnerström E, Soliman S. Low-dose formoterol Turbuhaler® (Oxis®) b.i.d., a 3-month placebo-controlled comparison with terbutaline (q.i.d.). Respir Med 1998; 92: 1040-1045.
26. Ekström T, Ringdal N, Tukiainen P, Runnerström E, Soliman S. A 3-month comparison of formoterol with terbutaline via Turbuhaler. A placebo-controlled study. Ann Allergy Asthma Immunol 1998; 81: 225-230.
27. Wong CS, Pavord ID, Williams J, Britton JR, Tattersfield AE. Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet 1990; 336: 1396-1399.
28. 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology. Drug Saf 1994; 11: 259-283.
29. 2-agonists in the treatment of asthma? Chest 1995; 107: 1116-1124.